Management of Headaches in Adults with Comorbid Autism and ADHD
Medication Considerations
- The American Academy of Neurology recommends considering atomoxetine as a first-line non-stimulant option for ADHD in adults with comorbid autism, due to its efficacy and fewer cardiovascular side effects compared to stimulants 2
- Clonidine alone is associated with potential adverse effects including somnolence, fatigue, irritability, insomnia, nightmares, dry mouth, sedation, bradycardia, and syncope, and should be used cautiously 1
- Non-stimulants like atomoxetine provide "around-the-clock" effects without the rebound/crash experienced with stimulants, and may be better tolerated in patients experiencing stimulant side effects 3, 2
Dosing and Administration
- For atomoxetine, start with a lower dose and gradually titrate upward, with a daily dose that can be split into two equal doses administered in the morning and evening to reduce adverse effects 1, 3
- Set appropriate expectations regarding delayed onset of action (6-12 weeks for full effect) when using atomoxetine 1, 2
- If continuing Clonidine, the recommended starting dose is 0.1 mg tablet at bedtime, which can be increased to twice-daily administration, with a maximum recommended dose of 0.4 mg/day 1
Monitoring and Follow-up
- Monitor vital signs, particularly blood pressure and heart rate, at each follow-up visit when using atomoxetine or Clonidine 1
- Assess for common side effects of atomoxetine including decreased appetite, headache, stomach pain, nausea, dry mouth, and insomnia 2
- Regular reassessment of treatment efficacy for both ADHD and autism symptoms is essential when using atomoxetine or Clonidine 2